As of 2024-10-05, the EV/EBITDA ratio of Emergent BioSolutions Inc (EBS) is -14.63. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. EBS's latest enterprise value is 1,297.59 mil USD. EBS's TTM EBITDA according to its financial statements is -88.70 mil USD. Dividing these 2 quantities gives us the above EBS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.4x - 11.3x | 10.9x |
| Forward P/E multiples | 10.1x - 11.1x | 10.6x |
| Fair Price | (31.75) - (32.90) | (32.28) |
| Upside | -439.5% - -451.8% | -445.2% |
| Date | EV/EBITDA |
| 2024-10-04 | -14.63 |
| 2024-10-03 | -14.38 |
| 2024-10-02 | -14.53 |
| 2024-10-01 | -14.09 |
| 2024-09-30 | -14.02 |
| 2024-09-27 | -13.50 |
| 2024-09-26 | -13.37 |
| 2024-09-25 | -12.55 |
| 2024-09-24 | -12.66 |
| 2024-09-23 | -12.63 |
| 2024-09-20 | -12.92 |
| 2024-09-19 | -13.19 |
| 2024-09-18 | -13.14 |
| 2024-09-17 | -13.12 |
| 2024-09-16 | -13.35 |
| 2024-09-13 | -13.73 |
| 2024-09-12 | -13.58 |
| 2024-09-11 | -13.54 |
| 2024-09-10 | -13.67 |
| 2024-09-09 | -13.61 |
| 2024-09-06 | -13.51 |
| 2024-09-05 | -13.58 |
| 2024-09-04 | -13.44 |
| 2024-09-03 | -13.44 |
| 2024-08-30 | -14.00 |
| 2024-08-29 | -14.36 |
| 2024-08-28 | -14.36 |
| 2024-08-27 | -14.59 |
| 2024-08-26 | -14.61 |
| 2024-08-23 | -14.74 |
| 2024-08-22 | -14.72 |
| 2024-08-21 | -15.32 |
| 2024-08-20 | -14.81 |
| 2024-08-19 | -16.30 |
| 2024-08-16 | -15.48 |
| 2024-08-15 | -14.21 |
| 2024-08-14 | -13.54 |
| 2024-08-13 | -13.06 |
| 2024-08-12 | -13.00 |
| 2024-08-09 | -13.25 |
| 2024-08-08 | -14.05 |
| 2024-08-07 | -12.42 |
| 2024-08-06 | -14.94 |
| 2024-08-05 | -14.85 |
| 2024-08-02 | -15.09 |
| 2024-08-01 | -15.37 |
| 2024-07-31 | -16.68 |
| 2024-07-30 | -16.16 |
| 2024-07-29 | -17.93 |
| 2024-07-26 | -17.44 |